Nearly 17M U.S. Teens, Young Adults Eligible for GLP-1 Agonists

(MedPage Today) — Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions like obesity and type 2 diabetes, many lacked insurance or a routine place for healthcare, a cross-sectional…